|
1
|
Singh S, Fujii LL, Murad MH, et al: Liver
stiffness is associated with risk of decompensation, liver cancer,
and death in patients with chronic liver diseases: a systematic
review and meta-analysis. Clin Gastroenterol Hepatol. 11:1573–1584.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tanaka K, Ichikawa Y and Endo I: Liver
resection for advanced or aggressive colorectal cancer metastases
in the era of effective chemotherapy: a review. Int J Clin Oncol.
16:452–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leenders MW, Nijkamp MW and Borel Rinkes
IH: Mouse models in liver cancer research: a review of current
literature. World J Gastroenterol. 14:6915–6923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coviello E, Caputi G, Martinelli D,
Germinario CA and Prato R: Mortality trends for primary liver
cancer in Puglia, Italy. Eur J Cancer Prev. 19:417–423. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shiraha H, Yamamoto K and Namba M: Human
hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138.
2013.PubMed/NCBI
|
|
6
|
Baillargeon J, Snyder N, Soloway RD, et
al: Hepatocellular carcinoma prevalence and mortality in a male
state prison population. Public Health Rep. 124:120–126.
2009.PubMed/NCBI
|
|
7
|
Chen JG and Zhang SW: Liver cancer
epidemic in China: past, present and future. Semin Cancer Biol.
21:59–69. 2011. View Article : Google Scholar
|
|
8
|
Okuda K, Ohtsuki T, Obata H, et al:
Natural history of hepatocellular carcinoma and prognosis in
relation to treatment. Study of 850 patients. Cancer. 56:918–928.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lobry C, Oh P, Mansour MR, Look AT and
Aifantis I: Notch signaling: switching an oncogene to a tumor
suppressor. Blood. 123:2451–2459. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Elliman SJ, Howley BV, Mehta DS, Fearnhead
HO, Kemp DM and Barkley LR: Selective repression of the oncogene
cyclin D1 by the tumor suppressor miR-206 in cancers. Oncogenesis.
3:e1132014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Z, Fu Q, Lv J, Wang F and Ding K:
Prognostic implication of p27Kip1, Skp2 and Cks1 expression in
renal cell carcinoma: a tissue microarray study. J Exp Clin Cancer
Res. 27:512008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Newbold A, Salmon JM, Martin BP, Stanley K
and Johnstone RW: The role of p21 and p27 in HDACi-mediated tumor
cell death and cell cycle arrest in the Eμ-myc model of B-cell
lymphoma. Oncogene. Dec 2–2013.(Epub ahead of print). View Article : Google Scholar
|
|
13
|
Gao J, Zhao Y, Lv Y, et al: Mirk/Dyrk1B
mediates G0/G1 to S phase cell cycle progression and cell survival
involving MAPK/ERK signaling in human cancer cells. Cancer Cell
Int. 13:22013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei W, Ayad NG, Wan Y, et al: Degradation
of the SCF component Skp2 in cell-cycle phase G1 by the
anaphase-promoting complex. Nature. 428:194–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bashir T, Dorrello NV, Amador V,
Guardavaccaro D and Pagano M: Control of the SCF (Skp2-Cks1)
ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature.
428:190–193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen G, Wang Y, Garate M, Zhou J and Li G:
The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated
ubiquitin-proteasome system. Oncogene. 29:1498–1508. 2010.
View Article : Google Scholar
|
|
17
|
Cheng H, Meng J, Wang G, et al: Skp2
regulates subcellular localization of PPARgamma by MEK signaling
pathways in human breast cancer. Int J Mol Sci. 14:16554–16569.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Gao D, Fukushima H, et al: Skp2: a
novel potential therapeutic target for prostate cancer. Biochim
Biophys Acta. 1825:11–17. 2012.
|
|
19
|
Wei Z, Jiang X, Qiao H, et al: STAT3
interacts with Skp2/p27/p21 pathway to regulate the motility and
invasion of gastric cancer cells. Cell Signal. 25:931–938. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pateras IS, Apostolopoulou K, Koutsami M,
et al: Downregulation of the KIP family members p27 (KIP1) and p57
(KIP2) by SKP2 and the role of methylation in p57 (KIP2)
inactivation in nonsmall cell lung cancer. Int J Cancer.
119:2546–2556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saleem M, Maddodi N, Abu Zaid M, et al:
Lupeol inhibits growth of highly aggressive human metastatic
melanoma cells in vitro and in vivo by inducing apoptosis. Clin
Cancer Res. 14:2119–2127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Adhami VM, Siddiqui IA, Ahmad N, Gupta S
and Mukhtar H: Oral consumption of green tea polyphenols inhibits
insulin-like growth factor-I-induced signaling in an autochthonous
mouse model of prostate cancer. Cancer Res. 64:8715–8722. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishitani H, Sugimoto N, Roukos V, et al:
Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1
for proteolysis. EMBO J. 25:1126–1136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peng L, Xu Z, Zhou Y, et al: Effect of
rosiglitazone on cells cycle, apoptosis and expression of Skp2 and
p27Kip1 in hepatocellular carcinoma cell line. Zhonghua Gan Zang
Bing Za Zhi. 18:148–149. 2010.(In Chinese). PubMed/NCBI
|
|
25
|
Schulman BA, Carrano AC, Jeffrey PD, et
al: Insights into SCF ubiquitin ligases from the structure of the
Skp1–Skp2 complex. Nature. 408:381–386. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Huang W, Huang S, Du J and Huang C:
Screening of anti-cancer agent using zebrafish: comparison with the
MTT assay. Biochem Biophys Res Commun. 422:85–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sarzaeem A, Zare Mirakabadi A, Moradhaseli
S, Morovvati H and Lotfi M: Cytotoxic effect of ICD-85
(venom-derived peptides) on HeLa cancer cell line and normal LK
cells using MTT assay. Arch Iran Med. 15:696–701. 2012.PubMed/NCBI
|
|
28
|
Sylvester PW: Optimization of the
tetrazolium dye (MTT) colorimetric assay for cellular growth and
viability. Methods Mol Biol. 716:157–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Y, Wang Y, Cheng C, et al: A
relationship between p27 (kip1) and Skp2 after adult brain injury:
implications for glial proliferation. J Neurotrauma. 27:361–371.
2010. View Article : Google Scholar
|
|
30
|
Rosner M and Hengstschläger M: Tuberin
binds p27 and negatively regulates its interaction with the SCF
component Skp2. J Biol Chem. 279:48707–48715. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu D, Liu W, Wu G and Wan Y: Nuclear
translocation of Skp2 facilitates its destruction in response to
TGFbeta signaling. Cell Cycle. 10:285–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Foster JS, Fernando RI, Ishida N, Nakayama
KI and Wimalasena J: Estrogens down-regulate p27Kip1 in breast
cancer cells through Skp2 and through nuclear export mediated by
the ERK pathway. J Biol Chem. 278:41355–41366. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pavlides SC, Huang KT, Reid DA, et al:
Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth
stimulation and degradation of nuclear p27kip1: therapeutic
potential for endometrial cancer. Endocrinology. 154:4030–4045.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kudo M: Targeted therapy for liver cancer:
updated review in 2012. Curr Cancer Drug Targets. 12:1062–1072.
2012.PubMed/NCBI
|
|
35
|
Montalvo-Jave EE, Villegas-Alvarez F,
Montalvo-Arenas CE, et al: Liver transplantation: some advances in
liver cancer, live liver donation, and cell transplantation. A
literature review. Rev Gastroenterol Mex. 74:341–348. 2009.
|
|
36
|
Shanmugasundaram K, Block K, Nayak BK, et
al: PI3K regulation of the SKP-2/p27 axis through mTORC2. Oncogene.
32:2027–2036. 2013. View Article : Google Scholar :
|
|
37
|
Assoian RK and Yung Y: A reciprocal
relationship between Rb and Skp2: implications for restriction
point control, signal transduction to the cell cycle and cancer.
Cell Cycle. 7:24–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bashir T, Pagan JK, Busino L and Pagano M:
Phosphorylation of Ser72 is dispensable for Skp2 assembly into an
active SCF ubiquitin ligase and its subcellular localization. Cell
Cycle. 9:971–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Calvisi DF, Pinna F, Ladu S, et al: The
degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase
is genetically controlled in rodent liver cancer and contributes to
determine the susceptibility to the disease. Int J Cancer.
126:1275–1281. 2010.
|
|
40
|
Wei Z, Jiang X, Liu F, et al:
Downregulation of Skp2 inhibits the growth and metastasis of
gastric cancer cells in vitro and in vivo. Tumour Biol. 34:181–192.
2013. View Article : Google Scholar
|
|
41
|
Wu J, Lee SW, Zhang X, et al: Foxo3a
transcription factor is a negative regulator of Skp2 and Skp2 SCF
complex. Oncogene. 32:78–85. 2013. View Article : Google Scholar :
|
|
42
|
Wu L, Grigoryan AV, Li Y, et al: Specific
small molecule inhibitors of Skp2-mediated p27 degradation. Chem
Biol. 19:1515–1524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zheng XY, Ding W, Xie LP and Chen ZD:
Correlation of Skp2 and P27kip1 protein expression and
clinicopathological features of prostate cancer. Ai Zheng.
23:215–218. 2004.(In Chinese). PubMed/NCBI
|
|
44
|
Ben-Izhak O, Lahav-Baratz S, Meretyk S, et
al: Inverse relationship between Skp2 ubiquitin ligase and the
cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J
Urol. 170:241–245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Radke S, Pirkmaier A and Germain D:
Differential expression of the F-box proteins Skp2 and Skp2B in
breast cancer. Oncogene. 24:3448–3458. 2005. View Article : Google Scholar : PubMed/NCBI
|
